Loading…
Loading…
GILD · NASDAQ · Healthcare
“Most investors chase the next miracle drug while ignoring that Gilead's boring HIV franchise prints money more reliably than any biotech lottery ticket.”
— In the voice of Munger
Compute the compound annual growth rate for any investment period. The true annualized return that accounts for compounding.
Market Cap
$175.30B
P/E Ratio
20.60
Forward P/E
—
EPS
$6.84
PEG Ratio
0.86
Book Value
$18.25
Dividend Yield
2.28%
Profit Margin
28.90%
ROE
37.48%
Use the interactive cagr calculator with pre-loaded data for Gilead Sciences Inc. Adjust discount rates, growth assumptions, and projection horizons to model different scenarios.
Pre-loaded inputs for GILD: